As Top2α is expressed only in proliferating cells [46] and is overexpressed in many cancer cells, a combination therapy of an anthracycline and a Bmi1/Ring1A inhibitor, is expected to achieve similar specific killing of cancer cells through increased poisoning of Top2α, with reduced unwanted side effects. Here, TOP2A is linked to cancer.